Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP
Yuan Yuan(Cedars-Sinai Medical Center), Hamid Mirshahidi(Loma Linda University)
Cited by 120
Related Papers
Liver diseases: epidemiology, causes, trends and predictions
|Signal Transduction and Targeted Therapy|2025|205
CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial
|Nature Medicine|2025|189
Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial).
|Journal of Clinical Oncology|2020|68
Comprehensive Molecular Characterization of Mitochondrial Genomes in Human Cancers
|bioRxiv (Cold Spring Harbor Laboratory)|2017|64